[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  LongYield [@LongYield](/creator/twitter/LongYield) on x 4475 followers Created: 2025-07-18 22:03:56 UTC $ABT Abbott Laboratories Earnings Call Key Highlights: (1/2) 📈 Overall Financial Performance Q2 2025 organic sales (excluding COVID testing) rose 7.5%, with total reported growth of 6.9%; H1 2025 organic growth stood at 8%. Adjusted EPS for the quarter was $1.26, up XX% YoY and XX% sequentially, exceeding consensus estimates and reflecting double-digit bottom-line growth. Gross margin and operating margin both expanded by XXX basis points YoY, reaching XX% and XXXX% of sales, respectively. Full-year outlook reaffirmed despite macro headwinds, with expectations of continued high single-digit sales growth and double-digit EPS growth in H2. 🥛 Nutrition Segment Performance Sales grew XXX% in Q2, led by XXX% growth in Adult Nutrition, driven by continued strength of Ensure and Glucerna globally. Consumer demand remains robust for protein-rich and diabetes-specific nutritional products, underpinning consistent category leadership. Pediatric Nutrition showed moderate recovery as the segment moved beyond prior market share recovery dynamics. Segment remains aligned with long-term health and demographic trends, including aging populations and dietary wellness awareness. 🧪 Diagnostics Segment Overview Segment sales declined XXX% in Q2 due to COVID testing drop-off and volume-based procurement (VBP) challenges in China. Excluding COVID and China Core Lab, diagnostics grew 8%, with strong performance in the U.S., Europe, and Latin America. Over $X billion in total diagnostic headwinds for 2025, including lower foreign aid funding for HIV testing and slower-than-expected recovery in China. Despite current pressures, management reaffirmed strong long-term commitment to diagnostics, citing robust global demand and upcoming Alinity system launch. 💊 Established Pharmaceuticals Division (EPD) EPD delivered nearly X% growth in Q2, surpassing $X billion in quarterly sales across its “Key 15” emerging markets. Growth driven by demographic trends including rising middle class, higher birth rates, and increased demand for branded generics. Ten biosimilar regulatory filings completed across emerging markets, with initial launches expected in 2026. Strong portfolio tailoring and deep local market knowledge continue to reinforce competitive advantage and long-term scalability. 🫀 Medical Devices: Diabetes Care Diabetes Care sales reached $XXX billion, up XXXX% YoY, with U.S. Libre growth accelerating to nearly 26%. Growth driven across all segments: intensive insulin users, basal insulin users, and non-insulin users, with Libre now holding ~70% global CGM market share. Commercial coverage in the U.S. for non-insulin users has doubled over three years, now ~30%, supporting sustained volume growth. Upcoming dual-analyte (glucose + ketone) sensor seen as a significant innovation for intensive users, with broad pump integration underway and potential to unlock new prescription use cases, including with SGLT2 drugs.  XXX engagements  **Related Topics** [eps](/topic/eps) [h1](/topic/h1) [quarterly earnings](/topic/quarterly-earnings) [$abt](/topic/$abt) [abbott laboratories](/topic/abbott-laboratories) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/LongYield/status/1946330118982451279)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
LongYield @LongYield on x 4475 followers
Created: 2025-07-18 22:03:56 UTC
$ABT Abbott Laboratories Earnings Call Key Highlights: (1/2)
📈 Overall Financial Performance
Q2 2025 organic sales (excluding COVID testing) rose 7.5%, with total reported growth of 6.9%; H1 2025 organic growth stood at 8%.
Adjusted EPS for the quarter was $1.26, up XX% YoY and XX% sequentially, exceeding consensus estimates and reflecting double-digit bottom-line growth.
Gross margin and operating margin both expanded by XXX basis points YoY, reaching XX% and XXXX% of sales, respectively.
Full-year outlook reaffirmed despite macro headwinds, with expectations of continued high single-digit sales growth and double-digit EPS growth in H2.
🥛 Nutrition Segment Performance
Sales grew XXX% in Q2, led by XXX% growth in Adult Nutrition, driven by continued strength of Ensure and Glucerna globally.
Consumer demand remains robust for protein-rich and diabetes-specific nutritional products, underpinning consistent category leadership.
Pediatric Nutrition showed moderate recovery as the segment moved beyond prior market share recovery dynamics.
Segment remains aligned with long-term health and demographic trends, including aging populations and dietary wellness awareness.
🧪 Diagnostics Segment Overview
Segment sales declined XXX% in Q2 due to COVID testing drop-off and volume-based procurement (VBP) challenges in China.
Excluding COVID and China Core Lab, diagnostics grew 8%, with strong performance in the U.S., Europe, and Latin America.
Over $X billion in total diagnostic headwinds for 2025, including lower foreign aid funding for HIV testing and slower-than-expected recovery in China.
Despite current pressures, management reaffirmed strong long-term commitment to diagnostics, citing robust global demand and upcoming Alinity system launch.
💊 Established Pharmaceuticals Division (EPD)
EPD delivered nearly X% growth in Q2, surpassing $X billion in quarterly sales across its “Key 15” emerging markets.
Growth driven by demographic trends including rising middle class, higher birth rates, and increased demand for branded generics.
Ten biosimilar regulatory filings completed across emerging markets, with initial launches expected in 2026.
Strong portfolio tailoring and deep local market knowledge continue to reinforce competitive advantage and long-term scalability.
🫀 Medical Devices: Diabetes Care
Diabetes Care sales reached $XXX billion, up XXXX% YoY, with U.S. Libre growth accelerating to nearly 26%.
Growth driven across all segments: intensive insulin users, basal insulin users, and non-insulin users, with Libre now holding ~70% global CGM market share.
Commercial coverage in the U.S. for non-insulin users has doubled over three years, now ~30%, supporting sustained volume growth.
Upcoming dual-analyte (glucose + ketone) sensor seen as a significant innovation for intensive users, with broad pump integration underway and potential to unlock new prescription use cases, including with SGLT2 drugs.
XXX engagements
Related Topics eps h1 quarterly earnings $abt abbott laboratories stocks healthcare